blood cancer medicine

DASALIEVA 50mg Tablet: Next-Generation Tyrosine Kinase Inhibition for Ph+ Leukemia Management Are you searching for a reliable DASALIEVA 50mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is DASALIEVA 50mg? DASALIEVA 50mg is an oral targeted therapy containing the active pharmaceutical ingredient Dasatinib. Manufactured by Allieva Pharma Pvt Ltd, this 50mg tablet is a potent, second-generation tyrosine kinase inhibitor (TKI). It is specifically designed to treat cancers characterized by the Philadelphia chromosome (Ph+), offering a high-affinity alternative for patients who are resistant or intolerant to first-generation therapies like Imatinib. 1. Therapeutic Indications Chronic Myeloid Leukemia (CML): Indicated for newly diagnosed adult patients in the chronic phase, as well as those in accelerated or blast crisis phases who have shown resistance to prior therapies. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Used for adult patients with Ph+ ALL who are resistant or intolerant to prior treatment. Pediatric Oncology: Increasingly used for children with Ph+ CML in the chronic phase. 2. Mechanism of Action: Multi-Pathway Signal Blockade Bcr-Abl Inhibition: It binds to the active and inactive configurations of the Bcr-Abl kinase, the “on-switch“ for leukemia cell production. SRC Family Inhibition: Unlike first-generation TKIs, Dasatinib also inhibits the SRC family of kinases (SRC, LCK, YES, FYN), which are involved in cancer cell migration and survival. High Potency: It is estimated to be significantly more potent than Imatinib in vitro, allowing it to overcome many mutations that cause drug resistance in leukemia cells. 3. Administration and Dosage Management Standard Dosing: The typical dose for chronic phase CML is 100mg once daily (two 50mg tablets). For accelerated or blast phase CML/Ph+ ALL, the dose is often 140mg once daily. Administration: Tablets can be taken with or without food. They must be swallowed whole and never crushed or chewed, as this can affect absorption and increase toxicity risk. Consistency: For optimal therapeutic levels, the medication should be taken at the same time every day. Clinical Side Effects & Safety Monitoring Fluid Retention: Monitoring for pleural effusion (fluid around the lungs) or pericardial effusion. Patients should report any new shortness of breath or dry cough. Hematological Safety: Potential for myelosuppression (lowered blood counts); regular Complete Blood Count (CBC) monitoring is mandatory. Cardiovascular Monitoring: Risk of QT prolongation and pulmonary arterial hypertension (PAH). Gastrointestinal Health: Potential for nausea, diarrhea, and abdominal pain. Drug Interactions: Avoid H2 blockers or Proton Pump Inhibitors (PPIs) as they can significantly reduce the absorption of Dasatinib. Why Source DASALIEVA 50mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s DASALIEVA with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Darzalex Faspro 1800mg (Daratumumab) Liquid for Injection Darzalex Faspro 1800 mg Injection contains Daratumumab, a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Daratumumab is an immunotherapy medicine that helps the immune system identify and destroy cancer cells. Darzalex Faspro is a subcutaneous formulation of Daratumumab combined with hyaluronidase, allowing faster administration compared to traditional intravenous infusions. Ernest Oncology supplies Darzalex Faspro 1800mg (Daratumumab) Liquid for Injection globally with secure packaging, competitive export pricing, and reliable worldwide delivery. Product Information (Text Format) Product Name: Darzalex Faspro Injection Generic Name: Daratumumab Strength: 1800mg Dosage Form: Liquid for Injection Therapeutic Class: Anti-Cancer / Immunotherapy / Monoclonal Antibody Packaging Type: Vial Route of Administration: Subcutaneous Injection Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Darzalex Faspro 1800mg Injection Darzalex Faspro (Daratumumab) Injection is used in the treatment of: • Multiple Myeloma • Relapsed or Refractory Multiple Myeloma • Newly Diagnosed Multiple Myeloma (in combination therapy) It is commonly used together with other anticancer medicines such as lenalidomide, bortezomib, or dexamethasone. How Darzalex Faspro Injection Works Daratumumab works by targeting the CD38 protein found on multiple myeloma cells. By binding to this protein, the medicine helps the immune system recognize and destroy cancer cells. Administration Darzalex Faspro 1800mg Injection should only be administered by a qualified healthcare professional. • Administered subcutaneously (under the skin) • Injection usually takes 3–5 minutes • Treatment schedule depends on the patient’s treatment plan and response Possible Side Effects Some patients may experience: • Fatigue • Nausea • Injection site reactions • Low blood cell counts • Fever • Increased risk of infections Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store at 2°C – 8°C (Refrigerated) • Do not freeze • Protect from light • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier 🌐 Websites www.oncologymedicinesupplier.com www.ernestvision.com www.ernestimpex.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

The Professional Guide to Acalnib 100mg (Acalabrutinib) Capsule: Targeted BTK Inhibition & Global Supply In the modern treatment of hematological malignancies, Acalnib 100mg Capsule has become a vital targeted therapy. As a leading pharmaceutical exporter from India, Ernest Oncology (Group of Ernest Pharmaceutical Pvt. Ltd.) ensures that healthcare providers and institutional buyers in the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia have seamless access to this high-quality Acalabrutinib generic. What is Acalnib 100mg (Acalabrutinib)? Acalnib 100mg contains Acalabrutinib, a potent and highly selective second-generation Bruton's Tyrosine Kinase (BTK) inhibitor. BTK is a key enzyme in the B-cell receptor signaling pathway, which is essential for the survival, proliferation, and spread of malignant B-cells. Acalnib is engineered to offer improved selectivity, potentially leading to fewer off-target side effects compared to earlier-generation BTK inhibitors. Therapeutic Indications Acalnib 100mg is globally recognized for the treatment of adult patients with: Chronic Lymphocytic Leukemia (CLL): Both as a first-line treatment and for patients who have relapsed or are refractory. Small Lymphocytic Lymphoma (SLL): Often treated with the same protocols as CLL due to their biological similarities. Mantle Cell Lymphoma (MCL): Specifically for adult patients who have received at least one prior therapy for their malignancy. Mechanism of Action Acalnib works through a precise molecular mechanism: Selective Binding: It forms a covalent bond with a specific cysteine residue in the BTK active site. Signal Blockade: This inhibition stops the B-cell receptor (BCR) signaling pathway. Halting Progression: By disrupting these signals, Acalnib prevents the growth and survival of cancerous B-cells, leading to tumor shrinkage and disease stabilization. Product Specifications & Clinical Usage Technical Specifications Active Ingredient: Acalabrutinib (100 mg) Form: Oral Capsule. Manufacturer: Hetero Healthcare Ltd. (marketed globally via Ernest Oncology). Packaging: 1 Bottle of 30 Capsules. Storage: Store at room temperature between 20°C and 25°C (68°F and 77°F). Keep in the original container to protect from light and moisture. Dosage and Administration Standard Dose: The recommended dose is 100 mg (one capsule) taken twice daily (approximately 12 hours apart). Method: Capsules should be swallowed whole with a glass of water. Do not open, break, chew, or crush the capsules. Dietary Note: Acalnib can be taken with or without food. Antacid Warning: Avoid taking proton pump inhibitors (PPIs) while on Acalnib. If you must use antacids, take them at least 2 hours before or 2 hours after your Acalnib dose. Safety & Side Effects Common side effects may include: Headache and fatigue. Diarrhea or nausea. Musculoskeletal (muscle, bone, or joint) pain. Upper respiratory tract infections. Serious Precautions: Acalnib may increase the risk of bleeding or heart rhythm problems (like atrial fibrillation). Regular blood count (CBC) monitoring is required to manage potential anemia or low platelet counts. Why Partner with Ernest Oncology for Global Export? Ernest Oncology specializes in the specialized logistics and regulatory compliance required for high-value oncology medications like Acalnib 100mg. Global Wholesale Reach: We are a verified exporter to major markets, including the USA, UK, UAE, Australia, and Singapore, supporting hospital tenders and large-scale distributors. Bulk Supplier Advantage: We offer competitive B2B pricing for institutional buyers across Africa and the Middle East, ensuring affordable access to targeted cancer therapies. Compliance & Quality: Our shipments are accompanied by all necessary regulatory documentation, including Certificate of Analysis (CoA) and Country of Origin (COO), and are packed in climate-controlled conditions. 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenakast 25mg Capsule (Lenalidomide): Comprehensive Clinical Profile & Global Supply Guide Lenakast 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. As a structural analogue of thalidomide, Lenakast 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Manufactured by Aprazer Healthcare, Lenakast is a trusted choice for oncology centers worldwide. Therapeutic Indications and Clinical Usage Lenakast 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lenakast 25mg Works Lenakast exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-α and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenakast 25mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lenakast. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care, adequate hydration, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the capsules directly to avoid accidental skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ WHO-GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenmid 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Cipla Ltd., a global pharmaceutical leader, Lenmid 25mg is recognized for its high efficacy, safety standards, and role in extending survival rates for patients worldwide. Therapeutic Indications and Clinical Usage Lenalidomide 25 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for newly diagnosed patients or those who have failed at least one prior therapy. It is also the gold standard for maintenance therapy post-autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for transfusion-dependent anemia caused by low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies. Follicular & Marginal Zone Lymphoma: Often used in combination with Rituximab for patients previously treated for these indolent lymphomas. Mechanism of Action: How Lenmid 25mg Works Lenmid exerts its anti-cancer effects through a multi-faceted biological approach: Direct Cytotoxicity: It binds to the cereblon E3 ubiquitin ligase complex, leading to the degradation of essential transcription factors, which triggers apoptosis (programmed cell death) in malignant cells. Immune System Enhancement: It stimulates the production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-$gamma$), which enhances the activity of T-cells and Natural Killer (NK) cells to actively destroy tumors. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors like VEGF, effectively starving the tumor of the blood supply it needs to grow. Anti-Inflammatory Action: It reduces the production of pro-inflammatory cytokines such as TNF-$alpha$, altering the bone marrow microenvironment to make it less hospitable for cancer cells. Dosage and Administration Guidelines Standard Regimen: Typically administered in 28-day cycles. In multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day break. Method of Intake: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Timing: Can be taken with or without food, but should be taken at the same time every day to maintain consistent blood levels. Renal Monitoring: Since Lenalidomide is primarily excreted by the kidneys, dosage adjustments are vital for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenmid 25mg involves proactive monitoring of the following: 1. Hematological Support Common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory. If counts drop significantly, a dose reduction or temporary treatment interruption is standard practice. 2. Thromboembolism Prophylaxis Patients taking Lenmid have an increased risk of venous thromboembolism (blood clots). Standard care involves prescribing prophylactic anticoagulants (like aspirin or heparin) concurrently with the medication. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is structurally related to thalidomide and is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Patients may report fatigue, diarrhea, muscle cramps, or skin rashes. These are typically managed through adequate hydration, supportive care, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Handling: Caregivers should handle capsules with care and avoid direct skin contact with the powder inside Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383

Fludacel 50mg (Fludarabine) Injection Fludacel 50mg Injection contains Fludarabine, a chemotherapy medicine used in the treatment of certain types of blood cancers, particularly Chronic Lymphocytic Leukemia (CLL). It belongs to the class of medicines known as antimetabolites, which work by interfering with the growth and multiplication of cancer cells. Fludarabine injections are commonly administered in hospitals and oncology treatment centers under the supervision of qualified healthcare professionals. Ernest Oncology supplies Fludacel 50mg (Fludarabine) Injection worldwide with secure packaging, competitive export pricing, and reliable international delivery. Product Information (Text Format) Product Name: Fludacel Injection Generic Name: Fludarabine Strength: 50mg Dosage Form: Injection Therapeutic Class: Anti-Cancer / Antimetabolite Packaging Type: Vial Route of Administration: Intravenous (IV) Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Fludacel 50mg Injection Fludacel (Fludarabine) Injection is used in the treatment of: • Chronic Lymphocytic Leukemia (CLL) • Certain types of blood cancers • Non-Hodgkin’s Lymphoma (in some treatment protocols) It helps slow the growth and spread of cancer cells in the body. How Fludacel Injection Works Fludarabine works by interfering with the DNA synthesis of cancer cells, preventing them from growing and multiplying. This action helps slow down the progression of cancer and destroy abnormal cells. Administration Fludacel 50mg Injection should only be administered by a qualified healthcare professional. Dosage depends on: • Patient’s body weight • Type and stage of cancer • Treatment protocol • Patient’s overall health condition The medicine is administered intravenously in hospitals or specialized oncology treatment centers. Possible Side Effects Some patients may experience: • Nausea and vomiting • Fatigue • Fever • Low blood cell counts • Increased risk of infections • Weakness Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store below 25°C • Protect from light • Keep in a cool and dry place • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export oncology medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India Group of Ernest Pharmaceutical Pvt. Ltd. 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

Deczuba 50mg (Decitabine) Injection Deczuba 50mg Injection contains Decitabine, a chemotherapy medicine used in the treatment of certain blood disorders and cancers, particularly Myelodysplastic Syndromes (MDS) and some forms of leukemia. It belongs to the class of medicines known as hypomethylating agents, which help restore normal function in bone marrow cells and slow the growth of abnormal cells. Decitabine injections are commonly administered in hospitals or oncology treatment centers under the supervision of qualified healthcare professionals. Ernest Oncology supplies Deczuba 50mg (Decitabine) Injection worldwide with secure packaging, competitive export pricing, and reliable international delivery. Product Information (Text Format) Product Name: Deczuba Injection Generic Name: Decitabine Strength: 50mg Dosage Form: Injection Therapeutic Class: Anti-Cancer / Hypomethylating Agent Packaging Type: Vial Route of Administration: Intravenous (IV) Manufacturer: Pharmaceutical Exporter: Ernest Oncology / Ernest Pharmaceutical Pvt. Ltd. Country of Origin: India Uses of Deczuba 50mg Injection Deczuba (Decitabine) Injection is used in the treatment of: • Myelodysplastic Syndromes (MDS) • Acute Myeloid Leukemia (AML) • Certain blood cancers and bone marrow disorders It helps improve blood cell production and slows the progression of abnormal bone marrow cells. How Deczuba Injection Works Decitabine works by inhibiting DNA methylation, which helps reactivate genes responsible for normal cell growth and differentiation. This action slows the growth of abnormal cancer cells and improves bone marrow function. Administration Deczuba 50mg Injection should only be administered by a qualified healthcare professional. Dosage depends on: • Patient’s body weight • Type and stage of disease • Treatment protocol • Patient’s overall medical condition The medicine is administered intravenously in hospitals or oncology treatment centers. Possible Side Effects Some patients may experience: • Fatigue • Nausea and vomiting • Fever • Low blood cell counts • Increased risk of infections • Weakness Patients should consult their healthcare provider if side effects persist or worsen. Storage Instructions • Store below 25°C • Protect from light • Keep in a cool and dry place • Keep out of reach of children Why Choose Ernest Oncology? Ernest Oncology, a group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export oncology medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India Group of Ernest Pharmaceutical Pvt. Ltd. 📞 Contact Ernest Oncology—Global Oncology Medicine Supplier [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp https://wa.me/919359902383 +91 93599 02383

Thalidomide 100mg Capsule: Immunomodulatory and Anti-Angiogenic Therapy for Multiple Myeloma and ENL Are you searching for a reliable Thalidomide 100mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted immunomodulatory agents. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Thalidomide 100mg? Thalidomide 100mg is an oral therapeutic agent containing the active pharmaceutical ingredient Thalidomide. Once known primarily for other uses, it has been repurposed as a powerful Immunomodulatory Drug (IMiD). It is a cornerstone in the treatment of plasma cell dyscrasias and specific inflammatory conditions. Due to its potent nature, it is distributed under strict regulatory oversight to ensure patient safety and therapeutic efficacy. 1. Therapeutic Indications Multiple Myeloma: Used in combination with Dexamethasone for patients with newly diagnosed multiple myeloma. It is also utilized in relapsed or refractory cases. Erythema Nodosum Leprosum (ENL): An essential treatment for the cutaneous manifestations of moderate to severe ENL (a complication of leprosy). It is also used as maintenance therapy to prevent and limit the recurrence of skin lesions. Off-Label Oncology Use: Occasionally utilized in research-backed protocols for specific solid tumors and myelodysplastic syndromes where anti-angiogenic properties are required. 2. Mechanism of Action: Multi-Faceted Attack Immunomodulation: It alters the production of cytokines, specifically inhibiting Tumor Necrosis Factor-alpha (TNF-α), which is a key driver of inflammation and cancer cell survival. Anti-Angiogenesis: It blocks the formation of new blood vessels (angiogenesis) by interfering with growth factors like VEGF and bFGF. This effectively “starves“ tumors of the nutrients needed to expand. Direct Anti-Tumor Effect: It induces cell cycle arrest and apoptosis (programmed cell death) in malignant plasma cells by disrupting their interaction with the bone marrow microenvironment. 3. Administration and Dosing Management Standard Dosing: For Multiple Myeloma, the typical dose ranges from 100mg to 200mg daily. For ENL, dosing is adjusted based on the severity of the reaction. Timing: It is generally recommended to take the capsule once daily at bedtime, at least 1 hour after the evening meal, to minimize sedation. Safety Handling: Capsules must be swallowed whole. Healthcare providers and caregivers should handle the medication with caution; direct contact with the powder inside the capsule should be avoided. Clinical Side Effects & Safety Monitoring eratogenicity (Birth Defects): This is the most critical risk. Thalidomide must never be used by pregnant women. Male and female patients must strictly adhere to specialized Risk Evaluation and Mitigation Strategies (REMS). Peripheral Neuropathy: Potential for tingling, numbness, or pain in the hands and feet. Early detection is vital to prevent permanent nerve damage. Venous Thromboembolism (VTE): Increased risk of blood clots (DVT or Pulmonary Embolism), especially when combined with steroids. Prophylactic blood thinners are often prescribed. Drowsiness & Sedation: Patients are advised to avoid heavy machinery or driving until their reaction to the drug is known. Why Source Thalidomide 100mg from Ernest Oncology? Verified Authenticity: Direct sourcing of high-integrity Thalidomide with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Lynide 5mg Capsule (Lenalidomide): Precision Immunomodulatory Therapy for Oncology Care Lynide 5mg Capsule is a high-efficacy oral antineoplastic and immunomodulatory medication containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Glenmark Pharmaceuticals, a globally recognized leader in high-quality medicine, Lynide belongs to the class of drugs known as Immunomodulatory Imide Drugs (IMiDs). The 5mg strength is a vital dosage form used extensively for maintenance therapy, precise dose titration, and the management of chronic hematological malignancies. Therapeutic Indications and Clinical Usage Lynide 5mg is integrated into international oncology protocols for the management of several complex conditions: Multiple Myeloma (MM) Maintenance: Used as a long-term strategy following an autologous stem cell transplant (ASCT) to prolong progression-free survival and prevent disease relapse. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Administered in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lynide 5mg Works Lynide exerts a multi-pathway biological effect to combat malignant cells while enhancing the body's natural defenses: Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex. This leads to the targeted degradation of essential transcription factors that malignant cells rely on for survival. Immune System Activation: It stimulates the proliferation and activity of T-cells and Natural Killer (NK) cells, significantly increasing the body's innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the development of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are known to promote the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration Guidelines Administration: Lynide 5 mg is an oral medication. Capsules must be swallowed whole with water. Do not open, crush, or chew the capsules. Consistency: It should be taken at approximately the same time each day, with or without food. Cycle-Based Therapy: In many maintenance protocols, it is taken daily on a 21-day or 28-day cycle. Always adhere to the specific regimen prescribed by your hematologist-oncologist. Dose Flexibility: The 5 mg strength allows clinicians to precisely adjust the dose to manage hematological toxicities or accommodate renal impairment. Safety Profile and Clinical Monitoring Due to its potent biological activity, Lynide 5 mg requires vigilant medical oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Risk: Lenalidomide increases the risk of blood clots. Prophylactic anticoagulation (e.g., Aspirin) is frequently prescribed concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients, regardless of gender or age. Common Side Effects: These may include fatigue, diarrhea, muscle cramps, skin rashes, and nausea. Storage and Global Handling Instructions Temperature: Store at room temperature (20°C to 25°C). Original Packaging: Keep capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately with soap and water. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

VENCLEXTA 100MG Tablet (Venetoclax) Exporter & Global Oncology Supplier – Ernest Oncology VENCLEXTA 100MG Tablet contains Venetoclax, an advanced targeted anti-cancer medicine used primarily for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). Ernest Impex is a trusted pharmaceutical exporter from India, supplying VENCLEXTA 100MG tablets globally to oncology hospitals, pharmaceutical distributors, cancer treatment centers, and healthcare procurement agencies. Pharmaceutical importers and healthcare providers across Washington (USA), London (UK), Riyadh (Saudi Arabia), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica) rely on Ernest Impex for bulk supply of Venetoclax tablets with reliable global logistics and competitive export pricing. What is VENCLEXTA 100MG Tablet? VENCLEXTA 100MG Tablet contains Venetoclax, a BCL-2 inhibitor used as targeted therapy for certain blood cancers. The drug works by blocking the BCL-2 protein, which helps cancer cells survive. Cancer cells in diseases such as CLL and AML rely heavily on the BCL-2 protein to avoid programmed cell death. By inhibiting this protein, Venetoclax allows cancer cells to undergo apoptosis (natural cell death). Because of its targeted mechanism, Venetoclax has become an important breakthrough therapy in hematology and oncology treatments worldwide. Mechanism of Action The active ingredient Venetoclax selectively inhibits the B-cell lymphoma-2 (BCL-2) protein, which regulates cell survival. By blocking BCL-2, Venetoclax: • Restores the natural process of cancer cell death • Prevents survival of abnormal leukemia cells • Reduces tumor burden • Improves treatment outcomes in leukemia patients This targeted mechanism makes VENCLEXTA tablets highly effective for certain blood cancers. Medical Uses of VENCLEXTA 100MG Tablet VENCLEXTA tablets are commonly prescribed for: • Chronic Lymphocytic Leukemia (CLL) • Small Lymphocytic Lymphoma (SLL) • Acute Myeloid Leukemia (AML) in combination therapy • Targeted treatment for hematologic malignancies • Patients with relapsed or refractory leukemia Venetoclax is widely used in advanced hematology and oncology treatment programs worldwide. Product Information Product Name: VENCLEXTA 100MG Tablet Generic Name: Venetoclax Strength: 100 mg Dosage Form: Oral Tablet Therapeutic Category: Anti-Cancer / BCL-2 Inhibitor Packaging: Blister pack / Export carton packaging Shelf Life: 24–36 months Storage: Store below 25°C in a cool and dry place Benefits of VENCLEXTA Tablets • Advanced targeted therapy for leukemia treatment • Helps eliminate abnormal cancer cells • Effective treatment for CLL, SLL, and AML • Oral tablet for convenient long-term therapy • Widely used in modern hematology treatment protocols • Proven targeted therapy for blood cancers Why Choose Ernest Oncology? Ernest Impex is a leading pharmaceutical exporter from India, supplying high-quality medicines to pharmaceutical distributors, hospitals, and healthcare institutions worldwide. Key advantages include • GMP-certified pharmaceutical sourcing • Competitive export pricing for bulk buyers • Reliable international pharmaceutical distribution network • OEM and private labeling options available • Fast international delivery via DHL, Aramex & Air Cargo • Trusted supplier of oncology medicines and specialty drugs Export Documentation Provided Ernest Oncology provides complete export documentation for international pharmaceutical shipments, including • Certificate of Analysis (COA) • Material Safety Data Sheet (MSDS) • Batch Release Certificate • Commercial Invoice • Packing List • Airway Bill / Shipping Documents • GMP Certificate • Certificate of Origin (if required) These documents ensure smooth customs clearance and regulatory compliance for pharmaceutical imports worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 Direct WhatsApp https://wa.me/919359902383